Transosseous Cannula Kit for Superior Hypogastric Plexus Blockade

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current techniques for neurolytic blockade of the superior hypogastric plexus face anatomical limitations and complications such as ureter injury, nerve root injury, dural sac injury, vascular injury, and disc infection, particularly in patients with pelvic or vertebral anatomical alterations and pathologies like L5-S1 degenerative disc disease, spondylolisthesis, and other osteoarticular issues.

Innovation Solution

A new transosseous technique using a bone transfixation cannula, probe, and infusion needle kit to perform neurolytic blockade through the S1 vertebral body, minimizing complications by ensuring precise placement and avoiding critical structures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If retroperitoneal access technique is used, then neurolytic blockade can be performed, but anatomical changes in pelvis and axial axis make it difficult or impossible to perform

Engineering Contradiction:

Improvesuccess rate of neurolytic blockadeVSAvoidapplicability to patients with anatomical alterations

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent inverts the traditional approach by accessing the superior hypogastric plexus through the sacrum (S1-S2) rather than through the retroperitoneal space or L5-S1 disc. This reverse anatomical approach allows needle insertion from a location (sacral region) that remains accessible even when L5-S1 anatomy is distorted by degenerative changes, spondylolisthesis, or other pathologies, thereby resolving the contradiction between procedural reliability and adaptability to anatomical variations

Inventive Principle:

Principle #13The other way round (Inversion)

2Reliability

If retroperitoneal access technique is used, then neurolytic blockade can be performed, but there is potential to injure important structures such as ureter, nerve roots, and vascular structures

Engineering Contradiction:

Improveeffectiveness of neurolytic blockadeVSAvoidrisk of injury to ureter, nerve roots, and vascular structures

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses the sacral bone (S1-S2) as an intermediary structure to reach the superior hypogastric plexus. By passing through the sacrum rather than directly through the retroperitoneal space, the technique creates a safer anatomical corridor that avoids direct exposure to vulnerable structures like the ureter and major vascular structures, thereby reducing injury risk while maintaining blockade effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the dimensional approach by accessing the target from a different anatomical plane - entering through the sacral region and proceeding anteriorly to reach the plexus, rather than approaching from the posterior retroperitoneal space. This dimensional shift in access route naturally avoids the hazardous anatomical structures encountered in traditional approaches

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

3Adaptability or versatility

If transdiscal access L5-S1 technique is used, then neurolytic blockade can be performed when retroperitoneal access is not feasible, but complications such as disc infection, root injury, and dural sac injury occur

Engineering Contradiction:

Improveability to perform blockade in patients with retroperitoneal access contraindicationsVSAvoidrisk of disc infection, root injury, and dural sac injury

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

Instead of accessing the superior hypogastric plexus through the L5-S1 disc (anterior approach), the patent inverts the approach by entering through the sacrum (S1-S2) and proceeding anteriorly to reach the same target. This inverted approach maintains adaptability for patients who cannot undergo retroperitoneal access while completely avoiding the L5-S1 disc, thereby eliminating the risk of discitis and associated complications

Inventive Principle:

Principle #13The other way round (Inversion)

4Reliability

If traditional techniques are used, then neurolytic blockade can be performed in standard anatomy, but patients with lumbar degenerative process, spondylolisthesis, or other osteoarticular pathologies cannot be treated

Engineering Contradiction:

Improvesuccess of neurolytic blockade in standard anatomyVSAvoidapplicability to patients with osteoarticular pathologies

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent inverts the traditional access route by entering through the sacrum (S1-S2) rather than through L5-S1 structures. Since the sacral region is anatomically distinct and typically spared from the degenerative changes affecting L5-S1 (such as disc degeneration, spondylolisthesis, or osteoarthritis), this inverted approach maintains high success rates for neurolytic blockade while expanding treatability to include patients with severe lumbar osteoarticular pathologies

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20260053530A1Instrument kit for transosseous upper hypogastric plexus neurolytic blockade

Publication Date: 2026.02.26 BARCELLOS ANDRÉ LUIZ LOYELO

AI summary

This is an instrument kit for transosseous superior hypogastric plexus neurolytic blockade characterized by containing a bone transfixation cannula (1), a probe (6) for obstructing the lumen of the bone transfixation cannula (1), a probe (9) for checking the positioning of the bone transfixation cannula (1), a needle (14) for infusion of the neurolytic agent, and a syringe containing a neurolytic agent.